Commercialization at UHN Analysis: $750K Raised
What is Commercialization at UHN?
Commercialization at UHN accelerates world-class medical research discoveries into global health solutions. Technologies developed at UHN form the basis of products and services in therapeutics, devices, and diagnostics. The organization has incubated successful companies including Trillium Therapeutics, which was acquired by Pfizer for $2.22B, and BlueRock Therapeutics, acquired by Bayer for $1B.
Location
Toronto, Canada
Employees
11-50
Founded
1999
Product Features & Capabilities
- Ex-vivo lung perfusion technology
- ADELA blood-based cancer diagnostics platform
- TREADWELL THERAPEUTICS cancer immunotherapy
- MEDLY THERAPEUTICS digital health platform for heart failure
- Porphyrin lipid nanoparticle drug delivery system
- Dry electrode technology for rehabilitation
Use Cases
Licensing ex-vivo lung perfusion for transplant availability improvement; Developing ADELA diagnostics for early cancer detection; Commercializing TREADWELL TCR T-cell therapies for cancer; Deploying MEDLY platform for chronic heart failure management; Using porphyrin LNPs to deliver therapeutics with 30–50% greater efficiency than current systems; Applying dry electrode technology to restore movement after stroke or paralysis
How much Commercialization at UHN raised
Funding - $750K
Other Considerations
Acquired Trillium Therapeutics by Pfizer for $2.22B; Acquired BlueRock Therapeutics by Bayer for $1B; Secured $60M financing round for ADELA; Raised $91M Series B for TREADWELL; Formed 10+ start-ups since 2014; 4 years of exit valuations for UHN start-ups since 2018
See something that needs updating? Suggest edits to this profile.